EpiVax, Inc.

Dec 23, 2019

EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020

Dec 20, 2019

On Eve of New Decade, EpiVax Re-Pledges Commitment to Improving Health Everywhere

Nov 06, 2019

EpiVax Announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports

Oct 22, 2019

Chugai Renews License to EpiVax's ISPRI In Silico Toolkit for Immunogenicity Assessment

Oct 02, 2018

Office of Generic Drugs (OGD/FDA) Awards $1M FDA Contract to CUBRC and EpiVax for Demonstration and Validation of Immunogenicity Risk Assessment Methods for Generic Peptide Drugs and Their Impurities

Dec 19, 2017

EpiVax Announces NIH-Funded Grant To Develop New Graves' Disease Therapy

Sep 25, 2017

EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology

Sep 18, 2017

$5.8 Million Awarded For Vaccine Engineering Will Use "Immune History" To Protect Against Bird Flu, A Collaboration Led By EpiVax

Aug 03, 2017

EpiVax Awarded "Innovation Voucher" to Accelerate the Development of a Game Changing Cancer Therapy